



# CBD (Cannabidiol)

CBD is a phytocannabinoid in the cannabis plant devoid of the psychoactive side effects



## 01 DESCRIPTION AND USES

- Phytocannabinoid present in the Cannabis Sativa plant has no psychotropic effects due to its affinity profile for cannabinoid CB1 and CB2 receptors, even it was found to be an inverse agonist at the human CB2 receptor, property
- Lot of reported pharmacological effects in several models of pathologies, ranging from inflammatory and neurodegenerative diseases, to epilepsy, autoimmune disorders like multiple sclerosis, arthritis, and cancer, among others.

## 02 PROPERTIES

### Mechanism of action

- CBD is able to antagonize cannabinoid CB1/CB2 receptor agonists WIN55212 and CP55940.
- Can act on the transient potential vanilloid receptor type-1 (TPVR-1), exhibiting an action similar to that elicited by the natural TPVR-1 agonist capsaicin.
- It was observed that CBD binds as an agonist to the serotonin receptor 5-HT1A and this interaction enhances its activity and allosterically regulates  $\mu$  and  $\delta$  opioid receptors.

### Opportunities

- New generation of drugs
- Innovative
- Focus on pets and geriatric diseases
- Multiple studies underway
- Multiple uses
- Good acceptance by the consumer
- Regulation changing and adapting
- Verv good prospects for the future

## 03 PRODUCT

- Pure Cannabidiol distributed by SUANFARMA is extracted from hemp and purified under EUGMP condition to achieve or quality goal: high CBD purity and no HTC content. Total detected impurities are below 0,07.
- Unlike other presentations, pure CBD allows adjusting the dose in the formulation, improving costs and distribution of the active ingredient in the final product.
- All hemp plantations are controlled by local authorities and drug enforcement agency, regularly inspected by them to ensure all the growing and collecting tasks all fully conducted under regulation.
- ASMF and in-house method of analysis are available and complied to the submission to local authorities if necessary.

## 04 FINAL DOSAGE EXAMPLES

Flavored pellets



Chewable tablets



Snacks



Oil spray/ Oil drop



## 05 BIBLIOGRAPHY

- **Cannabidiol: State of the art and new challenges for therapeutic applications.** Simona Pisanti a, \*,1, Anna Maria Malfitano a,1, Elena Ciaglia a, Anna Lamberti a, Roberta Ranieri a, Gaia Cuomo a, Mario Abate a, Giorgio Faggiana a, Maria Chiara Proto b, Donatella Fiore b, Chiara Laezza c, Maurizio Bifulco.
- **Cannabidiol, a constituent of Cannabis sativa, modulates sleep in rats. FEBS Letters 580, 4337–4345.** Murillo-Rodríguez, E., Millán-Aldaco, D., Palomero-Rivero, M., Mechoulam, R., & DruckerColín, R. (2006).
- **Antagonism of dopamine receptor 2 long affects cannabinoid receptor 1 signaling in a cell culture model of striatal medium spiny projection neurons. Molecular Pharmacology 89, 652–666.** Bagher, A. M., Laprairie, R. B., Kelly, M. E., & Denovan-Wright, E. M. (2016).
- **Pharmacokinetics, Safety, and Clinical Efficacy of Cannabidiol Treatment in Osteoarthritic Dogs.** Lauri-Jo Gamble 1, Jordyn M Boesch 1, Christopher W Frye 1, Wayne S Schwark 2, Sabine Mann 3, Lisa Wolfe 4, Holly Brown 5, Erin S Berthelsen 1, Joseph J Wakshlag 1.

**SUANFARMA**

For additional information please contact with:  
Carlos Ucero - [carlosucero@suanfarma.com](mailto:carlosucero@suanfarma.com)  
Product Manager Veterinary Specialist